One of the only industries that remains strong in the job market regardless of the state of the economy is health care. It doesn’t matter how much money people are spending on products and services – when they’re sick, they’re sick.
As health science goes, prosthesis technology is one that creeps many people out. It’s hard for most of us to imagine being without a limb and the way that science is able to make them realistic and usable is amazing while oddly offsetting at the same time.
If you’re one of those people who gets freaked out by prosthetic limbs, do not continue reading this article.
Around The Web
- Samsung's Gear S smartwatch doesn't need a phone to get online or make calls
- Tested: Slingbox M1
- Jabra Sport Pulse Wireless Earphones Also Include a Heart Rate Monitor
- What’s New With iOS 8?
- Nature shoots out an exploding lightning bolt right in a person's face
- BlackBerry Bold 9900, 9930 Will Run BlackBerry OS 7
For decades, robots have been used by people to assist with simple tasks. They work well in industry to automate processes and are exceptional for missions in conditions or circumstances too dangerous for humans, such as on Mars or on bombing runs. One organization is bringing new technology to the disabled to help them normalize their lives.
Sushi-lovers of the world, be afraid. Be very afraid. Or not?
This graphic by our friends at Mint breaks down the dangers of biting into raw, tsunami-induced radioactive fish. You may not need a lot of wasabi after all.
If recently injured patients with serious bleeding were to receive a cheap, widely available and easily administered drug to help their blood to clot, tens of thousands of lives could be saved every year, according to a paper published on-line today by The Lancet.
Dr Ian Roberts, Professor of Epidemiology at the London School of Hygiene and Tropical Medicine (LSHTM), UK, revealed that results from a trial show that early administration of tranexamic acid (TXA) to patients with recent, severe bleeding injuries saves lives, with no evidence of adverse effects from unwanted clotting.
The trial, named CRASH-2, was a large, randomised trial involving over 20,000 adult patients in 274 hospitals across 40 countries, and was funded by England’s National Institute for Health Research (NIHR) Health Technology Assessment programme. This is the first trial of TXA in injured patients, although smaller trials have shown that it reduces bleeding in patients undergoing major surgery.
TXA is an off-patent drug, manufactured by a number of different companies. The cost per gram is about £3 ($4.50).
The drug helps by reducing clot breakdown. Although this would be advantageous in patients with severe bleeding, doctors were worried that TXA might increase the risk of complications, such as heart attacks, strokes and clots in the lungs. The results of this large trial show that TXA reduces death from bleeding without any increase in these complications.
Researchers at National Jewish Health and the University of Colorado Anschutz Medical Campus have identified the precise protein fragment, or peptide, that can trigger diabetes in mice. The finding, published in the June 15, 2010, issue of the Proceedings of the National Academy of Sciences, supports an emerging theory about the origins of autoimmunity, and may lead to new diagnostic and therapeutic strategies in humans.
“Our findings contradict conventional wisdom, which suggests that insulin peptides that are well presented to the immune system trigger diabetes,” said John Kappler, PhD, Professor of Immunology at National Jewish Health. “We believe, however, that the peptide we identified triggers diabetes precisely because it is so poorly presented to the immune system.”
The immune system tries to delete all T cells that might cause autoimmune disease. During development in the thymus, immature T cells are exposed to “self” protein fragments, which are part of the organism. T cells that recognize and bind to them are destroyed. This process, however, is not foolproof, and autoimmune T cells do occasionally escape.
We’re upon a world first for remote medical procedure as Dr. André Ng is all set to perform the first ever heart rhythm treatment operation using the Catheter Robotics Remote Catheter Manipulation System. Dr. Ng will be able to perform the procedure from a remote location outside of the radiation zone using a robotic arm.
This procedure will take place at the Glenfield Hospital Leicester thanks to additional help and expertise from the University of Leicester and University Hospitals of Leicester.
The procedure Dr. Ng will conduct involves inserting thin wires (catheters) into veins near the groin and moving them through to the heart chambers. The catheters contain electrodes that will record and stimulate parts of the heart in order for Dr. Ng to identify the cause of the problem in the patient. Once the cause of the issue is found, the device will “burn” the tissue around the problem area to fix the abnormality. The procedure, called catheter ablation has been used for the past twenty years or so but never before using remote robotics technology.
Continue reading World’s First Remote Heart Operation Using Robotic Arm
Researchers from the University of the Mediterranean in Marseille, France have found evidence that suggest a virus common to peppers may have moved on to infect humans. Recently, a number of people have become ill and the RNA from the pepper mild mottle virus was found in their feces.
Didier Raoult of the UOM believes that it is possible the plant virus could be causing their symptoms. Of the 304 tested, 7 percent were found to have the virus in their feces. Those which did were more likely to have fever, abdominal pain and itching.